Therefore, despite the activation of p53-dependent cancer-promoting factors, oroxylin A acts by counteracting cancer-promoting effects through the activation of different pathways and it modulates p53 levels to promote its anticarcinogenic effects. The gene discussed is TP53; the disease is cancer.